Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin
Sreeneeranj Kasichayanula(Gilead Sciences (United States)), David W. Boulton(AstraZeneca (Poland)), Ming Chang, Steven C. Griffen(Io Therapeutics (United States)), Frank LaCreta(Fox Chase Cancer Center), Xiaoni Liu(Bristol-Myers Squibb (Germany)), Wen-Chyi Shyu(Princeton University)
Cited by 62
Related Papers
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans
|Journal of Clinical Investigation|2009|1.7k
Increased Toll-Like Receptor (TLR) 2 and TLR4 Expression in Monocytes from Patients with Type 1 Diabetes: Further Evidence of a Proinflammatory State
|The Journal of Clinical Endocrinology & Metabolism|2007|373
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
|The Lancet Diabetes & Endocrinology|2017|295
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
|Diabetes Care|2013|289
Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
|Clinical Pharmacokinetics|2013|277